Lung deposition and systemic availability of fluticasone Diskus and budesonide Turbuhaler in children

American Journal of Respiratory and Critical Care Medicine

Volumn 168, Issue 7, 2003, Pages 779-782

  Agertoft, Lone ^a   Pedersen, Søren ^b  

^a KOLDING HOSPITAL   (Denmark)

^b NONE

Author keywords

Children; Inhaled corticosteroids; Lung deposition; Pharmacokinetics; Study design

Indexed keywords

BUDESONIDE; CHARCOAL; FLUTICASONE; FLUTICASONE PROPIONATE;

ADOLESCENT; ARTICLE; ASTHMA; BLOOD ANALYSIS; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG UPTAKE; FEMALE; GASTROINTESTINAL TRACT; HUMAN; INHALER; MALE; METHODOLOGY; PRIORITY JOURNAL;

ADMINISTRATION, INHALATION; ADOLESCENT; ANDROSTADIENES; ASTHMA; BIOLOGICAL AVAILABILITY; BRONCHODILATOR AGENTS; BUDESONIDE; CHILD; CROSS-OVER STUDIES; FEMALE; GLUCOCORTICOIDS; HUMANS; INFUSIONS, INTRAVENOUS; LUNG; MALE; METERED DOSE INHALERS; TISSUE DISTRIBUTION;

EID: 0141727760     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/rccm.200302-200OC     Document Type: Article

References (33)

1. Borgström L, Bengtsson T, Derom E, Pauwels R. Variability in lung deposition of inhaled drug, within and between asthmatic patients, with a pMDI and a dry powder inhaler, Turbuhaler. Int J Pharm 2000;193:227-230.
2. Thorsson L, Edsbäcker S, Conradson TB. Lung deposition of budesonide from Turbuhaler is twice that from a pressurized metered dose inhaler P-MDI. Eur Respir J 1994;7:1839-1844.
3. Bisgaard H, Klug B, Sumby BS, Burnell PK. Fine particle mass from the Diskus inhaler and Turbuhaler inhaler in children with asthma. Eur Respir J 1998;11:1111-1115.
4. Persson G, Olsson B, Soliman S. The impact of inspiratory effort on inspiratory flow through Turbuhaler in asthmatic patients. Eur Respir J 1997;10:681-684.
5. Kaiser H, Aaronson D, Dockhorn R, Edsbacker S, Korenblat P, Kallen A. Dose-proportional pharmacokinetics of budesonide inhaled via Turbuhaler. Br J Clin Pharmacol 1999;48:309-316.
6. Everard ML, Dolovich M. In vivo measurement of lung dose. In: Bisgaard H, O'Callaghan C, Smaldone GC, editors. Drug delivery to the lung. New York: Marcel Decker; 2002. p. 173-209.
7. Agertoft L, Pedersen S. Systemic availability (lung deposition) of drug from two different dry powder inhalers in children with asthma [abstract]. Eur Respir J 2002;20:429s.
8. Pedersen S, Agertoft L. Systemic availability (lung deposition) of drug from two different dry powder inhalers in children with asthma [abstract]. J Allergy Clin Immunol 2003;111(2):S202.
9. Pedersen S, Steffensen G, Ohlsson SV. The influence of orally deposited budesonide on the systemic availability of budesonide after inhalation from a Turbuhaler. Br J Clin Pharmacol 1993;36:211-214.
10. Devadason SG, Everard ML, MacEarlan C, Roller C, Summers QA, Swift P, Borgström L, Le Souef PN. Lung deposition from the Turbuhaler in children with cystic fibrosis. Eur Respir J 1997;10:2023-2028.
11. Wildhaber JH, Devadason SG, Wilson JM, Roller C, Lagana T, Borgström L, Le Souef PN. Lung deposition of budesonide from turbuhaler in asthmatic children. Eur J Pediatr 1998;157:1017-1022.
12. Thorsson L, Edsbacker S, Kallen A, Lofdahl CG. Pharmacokinetics and systemic activity of fluticasone via Diskus and pMDI, and of budesonide via Turbuhaler. Br J Clin Pharmacol 2001;52:529-538.
13. Anhøj J. Thorsson L, Bisgaard H. Lung deposition of inhaled drugs increases with age. Am J Respir Crir Care Med 2000;162:1819-1822.
14. Agertoft L, Andersen A, Weibull E, Pedersen S. Systemic availability and pharmacokinetics of nebulized budesonide in pre-school children with asthma. Arch Dis Child 1999;80:241-247.
15. Falcoz C, Horton J, Mackie AE, Harding SM, Daley-Yates PT. Pharmacokinetics of fluticasone propionate inhaled via the Diskhaler and Diskus powder devices in patients with mild-to-moderate asthma. Clin Pharmacokinet 2000;39:31-37.
16. Mackie AE, McDowall JE, Falcoz C, Ventresca P, Bye A, Daley-Yates PT. Pharmacokinetics of fluticasone propionate inhaled via the Diskhaler and Diskus powder devices in healthy volunteers. Clin Pharmacokinet 2000;39(Suppl 1):23-30.
17. Martin RJ, Szefler SJ, Chinchilli VM, Kraft M, Dolovich M, Boushey HA, Cherniack RM, Craig TJ, Drazen JM, Fagan JK, et al. Systemic effect comparisons of six inhaled corticosteroid preparations. Am J Respir Crit Care Med 2002;165:1377-1383.
18. Olsson B, Borgström L, Asking L, Bondesson E. Effect of inlet throat on the correlation between measured fine particles dose and lung deposition. In: Dalby RN, Byron PR, Farr SJ, editors. Respiratory Drug Delivery V, Program and Proceedings. Buffalo Grove, IL: Interpharm Press, 1996. p. 273-281.
19. Leach CL, Davidson PJ, Hasselquist BE, Boudreau RJ. Lung deposition of hydrofluoroalkane-134a beclomethasone is greater than that of chlorofluorocarbon fluticasone and chlorofluorocarbon beclomethasone: a cross-over study in healthy volunteers. Chest 2002;122:510-516.
20. Newhouse MT. The current laboratory determination of "respirable mass" is not clinically relevant. J Aerosol Med 1998;11:S122-S132.
21. Asking L, Maayan C, Petterson G. Flutide Diskus less consistent than Pulmicort Turbuhaler with respect to in-vitro fine particle dose proportionality. Eur Respir J 2002;18:157s.
22. Barnes PJ, Pedersen S. Efficacy and safety of inhaled corticosteroids in asthma. Am Rev Respir Dis 1993;148:1-26.
23. Leach CL, Davidson PJ, Boudreau RJ. Improved airway targeting with the CFC-free HFA-beclomethasone metered-dose inhaler compared with CFC-beclomethasone. Eur Respir J 1998;12:1346-1353.
24. Leach CL. Improved delivery of inhaled steroids to the large and small airways. Respir Med 1998;92:3-8.
25. Thorsson L, Edsbäcker S, Conradson TB. Lung deposition of budesonide via Turbuhaler is twice that from a pressurized metered dose inhaler (MDI). Eur Respir J 1994;7:1839-1844.
26. Borgström L, Derom E, Ståhl E, Wåhlin-Boll E, Pauwels R. The inhalation device influences lung deposition and bronchodilating effect of terbutaline. Am J Respir Crit Care Med 1996;153:1636-1640.
27. Derom E, Borgstrom L, Van Schoor J, Lofroos AB, Pauwels R. Lung deposition and protective effect of terbutaline delivered from pressurized metered-dose inhalers and the Turbuhaler in asthmatic individuals. Am J Respir Crit Care Med 2001;164:1398-1402.
28. Pedersen S. Comparative study designs and what they show. Respir Med 2000;94(Suppl D):S40-S43.
29. Szefler SJ, Warner J, Staab D, Wahn U, Le Bourgeois M, Essen-Zandvliet EE, Arora S, Pedersen S. Switching from conventional to extrafine aerosol beclomethasone dipropionate therapy in children: a 6-month, open-label, randomized trial. J Allergy Clin Immunol 2002;110:45-50.
30. Busse WW, Brazinsky S, Jacobson K, Stricker W, Schmitt K, Vanden Burgt J, Donnell D, Harmon S, Colice GL. Efficacy response of inhaled beclomethasone dipropionate in asthma is proportional to dose and is improved by formulation with a new propellant. J Allergy Clin Immunol 1999;104:1215-1222.
31. Derom E, Van Schoor J, Verhaeghe W, Vincken W, Pauwels R. Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma. Am J Respir Crit Care Med 1999;160:157-161.
32. Agertoft L, Pedersen S. A randomized double blind dose reduction study to compare the minimal effective dose of budesonide Turbuhaler and fluticasone dipropionate Diskhaler. J Allergy Clin Immunol 1996;99:773-780.
33. Pedersen S, O'Byrne P. A comparison of the efficacy and safety of inhaled corticosteroids in asthma. Allergy 1997;52:1-34.